X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE STRIDES PHARMA SCIENCE TTK HEALTHCARE/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 19.5 62.9 31.1% View Chart
P/BV x 5.0 1.1 471.1% View Chart
Dividend Yield % 0.6 0.5 126.9%  

Financials

 TTK HEALTHCARE   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
STRIDES PHARMA SCIENCE
Mar-18
TTK HEALTHCARE/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs6631,147 57.8%   
Low Rs399642 62.1%   
Sales per share (Unadj.) Rs535.6317.2 168.8%  
Earnings per share (Unadj.) Rs15.97.8 203.3%  
Cash flow per share (Unadj.) Rs20.025.1 79.9%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.80.2 336.8%  
Book value per share (Unadj.) Rs137.6274.3 50.2%  
Shares outstanding (eoy) m7.7789.50 8.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.02.8 35.2%   
Avg P/E ratio x33.3114.0 29.2%  
P/CF ratio (eoy) x26.535.7 74.3%  
Price / Book Value ratio x3.93.3 118.3%  
Dividend payout %25.125.5 98.4%   
Avg Mkt Cap Rs m4,12780,058 5.2%   
No. of employees `0001.72.5 68.1%   
Total wages/salary Rs m6074,341 14.0%   
Avg. sales/employee Rs Th2,436.711,325.8 21.5%   
Avg. wages/employee Rs Th355.21,731.4 20.5%   
Avg. net profit/employee Rs Th72.5280.1 25.9%   
INCOME DATA
Net Sales Rs m4,16228,394 14.7%  
Other income Rs m61941 6.5%   
Total revenues Rs m4,22329,334 14.4%   
Gross profit Rs m1973,965 5.0%  
Depreciation Rs m321,540 2.1%   
Interest Rs m301,962 1.5%   
Profit before tax Rs m1971,403 14.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m7397 74.8%   
Profit after tax Rs m124702 17.6%  
Gross profit margin %4.714.0 33.9%  
Effective tax rate %37.06.9 533.7%   
Net profit margin %3.02.5 120.4%  
BALANCE SHEET DATA
Current assets Rs m1,62924,836 6.6%   
Current liabilities Rs m1,05818,993 5.6%   
Net working cap to sales %13.720.6 66.7%  
Current ratio x1.51.3 117.7%  
Inventory Days Days3071 42.0%  
Debtors Days Days34113 29.6%  
Net fixed assets Rs m55634,289 1.6%   
Share capital Rs m78895 8.7%   
"Free" reserves Rs m87823,651 3.7%   
Net worth Rs m1,06924,546 4.4%   
Long term debt Rs m15915,513 1.0%   
Total assets Rs m2,39965,437 3.7%  
Interest coverage x7.61.7 441.9%   
Debt to equity ratio x0.10.6 23.5%  
Sales to assets ratio x1.70.4 399.7%   
Return on assets %6.44.1 157.4%  
Return on equity %11.62.9 405.1%  
Return on capital %18.56.9 267.7%  
Exports to sales %0.80-   
Imports to sales %1.40-   
Exports (fob) Rs m33NA-   
Imports (cif) Rs m58NA-   
Fx inflow Rs m3315,697 0.2%   
Fx outflow Rs m63735 8.6%   
Net fx Rs m-3014,962 -0.2%   
CASH FLOW
From Operations Rs m1271,871 6.8%  
From Investments Rs m-1465,826 -2.5%  
From Financial Activity Rs m22-10,157 -0.2%  
Net Cashflow Rs m3-2,615 -0.1%  

Share Holding

Indian Promoters % 65.4 27.7 236.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 37.8 9.8%  
FIIs % 5.2 8.6 60.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 25.9 99.6%  
Shareholders   12,723 56,241 22.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   WYETH LTD  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  SUN PHARMA  IPCA LABS  

Compare TTK HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and Energy Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 60.1% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, TTK HEALTHCARE has posted a net profit of Rs 49 m (down 60.1% YoY). Sales on the other hand came in at Rs 1 bn (up 2.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

The Jet Airways Crisis in 6 Charts(Sector Info)

Mar 5, 2019

What happened to Jet Airways, once among top 3 airlines in India? Is it another Kingfisher in the making? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Mar 18, 2019 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE 5-YR ANALYSIS

COMPARE TTK HEALTHCARE WITH

MARKET STATS